To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Commons Chamber
Covid-19: Response and Excess Deaths - Thu 18 Apr 2024
Department for Business and Trade

Mentions:
1: Andrew Bridgen (Ind - North West Leicestershire) not elicit complete and long-term protective immunity against reinfection, how can we expect vaccines - Speech Link
2: Graham Stringer (Lab - Blackley and Broughton) corrected—so covid was essentially safe for children. - Speech Link
3: Neale Hanvey (Alba - Kirkcaldy and Cowdenbeath) -19.Let us move on to what we do not know. - Speech Link
4: Andrew Gwynne (Lab - Denton and Reddish) -19 pandemic were and, importantly, remain an essential tool in our fight against covid-19. - Speech Link

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023
Document: FOI 23/774 - attachment 2 (PDF)

Found: The pooled analyses demo nstrated that COVID -19 VACCINE ASTRAZENECA provides complete protecti on against

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 9 (PDF)

Found: As a rule , records that do not validate QA procedures are kept in a ‘holding area to be reviewed and

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 6 (PDF)

Found: As a rule , records that do not validate QA procedures are kept in a ‘holding area to be reviewed and

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 7 (PDF)

Found: if they do not receive the second dose of the Pfizer -BioNTech COVID- 19 vaccine b y week 6 after the

Departmental Publication (Transparency)
Home Office

Jul. 20 2023

Source Page: Non-technical summaries granted in 2023
Document: Non-technical summaries: projects granted in 2023, January to March (PDF)

Found: Most genetic alterations in our mice are inducible, meaning they do not lead to adverse effects until

Departmental Publication (Transparency)
Home Office

Jul. 20 2023

Source Page: Non-technical summaries granted in 2023
Document: Non-technical summaries: projects granted in 2023, April to June (PDF)

Found: trials with 2 trials per year = 5x2x3x10 = 300 Goat - 3 years of goat trials with 1 tr ials per year

Deposited Papers

Jul. 14 2023

Source Page: Nicotine vaping in England: an evidence update including health risks and perceptions 2022. A report commissioned by the Office for Health Improvement and Disparities. Incl. appendices. 1468p.
Document: Nicotine-vaping-in-England-2022-report.pdf (PDF)

Found: Studies are needed that compare long- term former smokers who do and do not vape, as well as studies

Departmental Publication (Policy and Engagement)
HM Treasury

Jun. 05 2023

Source Page: Treasury Minutes progress report – June 2023
Document: Treasury Minutes progress report – June 2023 (print) (PDF)

Found: COVID -19: Support for children’s education 4 COVID -19: Local Government finance 5 COVID -19

Departmental Publication (Transparency)
Home Office

Apr. 24 2023

Source Page: Non-technical summaries granted in 2022
Document: Non-technical summaries: projects granted in 2022, July to December (PDF)

Found: One of the major implications of long -covid happens to be its impact on patients with COVID -19.